MK0457 in Patients With Leukemia (0457-003)

• Status: Completed
• Trial end date: 2008-05-01

Summary

In this study participants with relapsed/refractory leukemia will be given MK-0457 in sequential cohorts and with varying treatment duration to determine the maximum tolerated dose (MTD) for MK-0457.

• Phase: Phase 1

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.